Literature DB >> 9870575

The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidine.

Paul S Tumber1, Dermot R Fitzgibbon.   

Abstract

The management of severe cancer pain may be problematic in spite of recent advances in pain management. A small percentage of patients with severe intractable pain and/or intractable side effects may require more aggressive interventional pain management strategies including the administration of medications continuously by the intrathecal route. A variety of medications, including morphine, bupivacaine, and clonidine, may be used intrathecally for the control of cancer pain. Optimal use of these medications requires individual titration to the patient's needs. We describe a case of severe cancer pain where these medications were used successfully by continuous intrathecal infusion and patient controlled intrathecal analgesia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870575     DOI: 10.1016/S0304-3959(98)00133-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

1.  Percutaneous CT-guided C1-2 cordotomy for intractable cancer pain.

Authors:  Dermot R Fitzgibbon
Journal:  Curr Pain Headache Rep       Date:  2009-08

Review 2.  Intrathecal analgesia for refractory cancer pain.

Authors:  Scott Newsome; Bridget K Frawley; Charles E Argoff
Journal:  Curr Pain Headache Rep       Date:  2008-08

Review 3.  Spinal drug delivery.

Authors:  T S Grabow; D Derdzinski; P S Staats
Journal:  Curr Pain Headache Rep       Date:  2001-12

Review 4.  Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.

Authors:  S Stacchiotti; A Gronchi; P Fossati; T Akiyama; C Alapetite; M Baumann; J Y Blay; S Bolle; S Boriani; P Bruzzi; R Capanna; A Caraceni; R Casadei; V Colia; J Debus; T Delaney; A Desai; P Dileo; S Dijkstra; F Doglietto; A Flanagan; S Froelich; P A Gardner; H Gelderblom; Z L Gokaslan; R Haas; C Heery; N Hindi; P Hohenberger; F Hornicek; R Imai; L Jeys; R L Jones; B Kasper; A Kawai; M Krengli; A Leithner; I Logowska; J Martin Broto; D Mazzatenta; C Morosi; P Nicolai; O J Norum; S Patel; N Penel; P Picci; S Pilotti; S Radaelli; F Ricchini; P Rutkowski; S Scheipl; C Sen; E Tamborini; K A Thornton; B Timmermann; V Torri; P U Tunn; M Uhl; Y Yamada; D C Weber; D Vanel; P P Varga; C L A Vleggeert-Lankamp; P G Casali; J Sommer
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.